Gastric cancer

Details

Review Type: Rapid

As per requests from jurisdictions, this project will be combined with PH0061 to be delivered together in order to streamline the process and work. Please refer to the project timelines for PH0061.

bulevirtide

Details

Key Milestones2
Call for patient/clinician input open22-Jan-25
Call for patient/clinician input closed18-Mar-25
Submission received09-Apr-25
Submission accepted25-Apr-25
Review initiated28-Apr-25
Draft CADTH review report(s) provided to sponsor for comment11-Jul-25
Deadline for sponsors comments22-Jul-25
CDA-AMC review report(s) and responses to comments provided to sponsor15-Aug-25
Expert committee meeting (initial)27-Aug-25
Draft recommendation issued to sponsorSeptember 09, 2025
To
September 11, 2025
Draft recommendation posted for stakeholder feedback18-Sep-25
End of feedback period03-Oct-25

odevixibat

Details

Key Milestones2
Call for patient/clinician input openJanuary 20, 2025
Call for patient/clinician input closedMarch 18, 2025
Submission receivedFebruary 28, 2025
Submission acceptedMarch 19, 2025
Clarification:

- Submission was not accepted for review on 17 Mar 2025

Review initiatedMarch 20, 2025
Draft CADTH review report(s) provided to sponsor for commentJune 05, 2025
Deadline for sponsors commentsJune 16, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorJuly 11, 2025
Expert committee meeting (initial)July 23, 2025
Draft recommendation issued to sponsorAugust 07, 2025
Draft recommendation posted for stakeholder feedbackAugust 14, 2025
End of feedback periodAugust 28, 2025

mirikizumab

Details

Key Milestones2
Call for patient/clinician input openJanuary 16, 2025
Call for patient/clinician input closedMarch 18, 2025
Submission receivedMarch 04, 2025
Submission acceptedMarch 19, 2025
Review initiatedMarch 20, 2025
Draft CADTH review report(s) provided to sponsor for commentJune 06, 2025
Deadline for sponsors commentsJune 17, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorJuly 11, 2025
Expert committee meeting (initial)July 23, 2025
Draft recommendation issued to sponsorAugust 06, 2025
Draft recommendation posted for stakeholder feedbackAugust 14, 2025
End of feedback periodAugust 28, 2025

mirvetuximab soravtansine

Details

Key Milestones2
Call for patient/clinician input openJanuary 17, 2025
Call for patient/clinician input closedMarch 18, 2025
Submission receivedMarch 03, 2025
Submission acceptedMarch 18, 2025
Review initiatedMarch 19, 2025
Draft CADTH review report(s) provided to sponsor for commentJune 13, 2025
Deadline for sponsors commentsJune 24, 2025
CDA-AMC review report(s) and responses to comments provided to sponsorJuly 31, 2025
Expert committee meeting (initial)August 13, 2025
Draft recommendation issued to sponsor-
Draft recommendation posted for stakeholder feedback-
End of feedback period-